A phase I/IIa study of the mRNA-based cancer immunotherapy CV9201 in patients with stage IIIB/IV non-small cell lung cancer.

Aged Aged, 80 and over Antigens, Neoplasm / genetics B-Lymphocytes / immunology Cancer Vaccines / genetics Carcinoma, Non-Small-Cell Lung / immunology Cells, Cultured Female Humans Immunotherapy / adverse effects Injection Site Reaction / etiology Lung Neoplasms / immunology Lymphocyte Activation Male Middle Aged Neoplasm Staging RNA, Messenger / administration & dosage Survival Analysis T-Lymphocytes / immunology
Active cancer immunotherapy CV9201 Clinical trial Immunomonitoring Non-small cell lung cancer mRNA

Journal

Cancer immunology, immunotherapy : CII
ISSN: 1432-0851
Titre abrégé: Cancer Immunol Immunother
Pays: Germany
ID NLM: 8605732

Informations de publication

Date de publication:
May 2019
Historique:
received: 13 07 2017
accepted: 09 02 2019
pubmed: 17 2 2019
medline: 23 5 2019
entrez: 17 2 2019
Statut: ppublish

Résumé

CV9201 is an RNActive

Identifiants

DOI: 10.1007/s00262-019-02315-x PMID: 30770959
pubmed: 30770959
doi: 10.1007/s00262-019-02315-x
pii: 10.1007/s00262-019-02315-x
doi:

Substances chimiques

Antigens, Neoplasm 0
Cancer Vaccines 0
RNA, Messenger 0

Types de publication

Clinical Trial, Phase I Clinical Trial, Phase II Journal Article Multicenter Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

799-812

Auteurs

Martin Sebastian (M)

University Medical Center of the Johannes Gutenberg-University, Mainz, Germany. martin.sebastian@kgu.de.
Medizinische Klinik II, Hämatologie/Onkologie, Rheumatologie, Infektiologie, HIV Klinikum der J.W. Goethe-Universität Frankfurt, Theodor-Stern-Kai 7, 60590, Frankfurt am Main, Germany. martin.sebastian@kgu.de.

Andreas Schröder (A)

CureVac AG, Tübingen, Germany.
Merck KGaA, Darmstadt, Germany.

Birgit Scheel (B)

CureVac AG, Tübingen, Germany.

Henoch S Hong (HS)

CureVac AG, Tübingen, Germany.
Merck KGaA, Darmstadt, Germany.

Anke Muth (A)

CureVac AG, Tübingen, Germany.

Lotta von Boehmer (L)

Klinik für Onkologie, UniversitätsSpital Zürich, Zurich, Switzerland.
Institute for Immunity, Transplantation and Infection, Stanford University School of Medicine, Stanford, CA, USA.

Alfred Zippelius (A)

Klinik für Onkologie, Universitätsspital Basel, Basel, Switzerland.

Frank Mayer (F)

Universitätsklinikum Tübingen, Tübingen, Germany.
Praxis und Tagesklinik, Friedrichshafen, Germany.

Martin Reck (M)

LungenClinic Grosshansdorf, Airway Research Center North (ARCN), German Center for Lung Research (DZL), Grosshansdorf, Germany.

Djordje Atanackovic (D)

Universitätsklinikum Hamburg-Eppendorf, Hamburg, Germany.
Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA.

Michael Thomas (M)

Internistische Onkologie der Thoraxtumoren, Thoraxklinik im Universitätsklinikum Heidelberg, Translational Lung Research Center Heidelberg (TLRC-H), Member of the German Center for Lung Research (DZL), Heidelberg, Germany.

Folker Schneller (F)

Klinikum rechts der Isar der TUM, Munich, Germany.

Jan Stöhlmacher (J)

Universitätsklinikum Carl Gustav Carus, Dresden, Germany.
Tumorgenetik Bonn, Bonn, Germany.

Helga Bernhard (H)

Klinikum Darmstadt GmbH, Darmstadt, Germany.

Andreas Gröschel (A)

Universitätsklinikum Aachen, Aachen, Germany.
Clemenshospital, Münster, Germany.

Thomas Lander (T)

CureVac AG, Tübingen, Germany.

Jochen Probst (J)

CureVac AG, Tübingen, Germany.
Sandoz GmbH, Langkampfen, Austria.

Tanja Strack (T)

CureVac AG, Tübingen, Germany.

Volker Wiegand (V)

CureVac AG, Tübingen, Germany.

Ulrike Gnad-Vogt (U)

CureVac AG, Tübingen, Germany.

Karl-Josef Kallen (KJ)

CureVac AG, Tübingen, Germany.
Kallen Medical Innovation GmbH, Frechen, Germany.

Ingmar Hoerr (I)

CureVac AG, Tübingen, Germany.

Florian von der Muelbe (F)

CureVac AG, Tübingen, Germany.

Mariola Fotin-Mleczek (M)

CureVac AG, Tübingen, Germany.

Alexander Knuth (A)

Klinik für Onkologie, UniversitätsSpital Zürich, Zurich, Switzerland.
National Center for Cancer Care and Research NCCCR, Hamad Medical Corporation, Doha, Qatar.

Sven D Koch (SD)

CureVac AG, Tübingen, Germany.
Sandoz Biopharmaceuticals, Department of Clinical Bioanalytics, Oberhaching, Germany.
ORCID: 0000-0002-6178-0448

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Personnes › Tranches d'âge › Adulte › Sujet âgé › A phase I/IIa study of the mRNA-based cancer...
questionsmedicales.fr › Personnes › Tranches d'âge › Adulte › Sujet âgé › Sujet âgé de 80 ans ou plus › A phase I/IIa study of the mRNA-based cancer...
questionsmedicales.fr › Facteurs biologiques › Antigènes › Antigènes néoplasiques › A phase I/IIa study of the mRNA-based cancer...
questionsmedicales.fr › Systèmes sanguin et immunitaire › Système immunitaire › Leucocytes › Agranulocytes › Lymphocytes › Lymphocytes B › A phase I/IIa study of the mRNA-based cancer...
questionsmedicales.fr › Mélanges complexes › Produits biologiques › Vaccins › Vaccins anticancéreux › A phase I/IIa study of the mRNA-based cancer...
questionsmedicales.fr › Maladies de l'appareil respiratoire › Tumeurs de l'appareil respiratoire › Tumeurs du poumon › Tumeurs des bronches › Carcinome bronchogénique › Carcinome pulmonaire non à petites cellules › A phase I/IIa study of the mRNA-based cancer...
questionsmedicales.fr › Cellules › Cellules cultivées › A phase I/IIa study of the mRNA-based cancer...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › A phase I/IIa study of the mRNA-based cancer...
questionsmedicales.fr › Thérapeutique › Biothérapie › Immunothérapie › A phase I/IIa study of the mRNA-based cancer...
questionsmedicales.fr › Troubles dus à des produits chimiques › Effets secondaires indésirables des médicaments › Réaction au site d'injection › A phase I/IIa study of the mRNA-based cancer...
questionsmedicales.fr › Maladies de l'appareil respiratoire › Tumeurs de l'appareil respiratoire › Tumeurs du poumon › A phase I/IIa study of the mRNA-based cancer...
questionsmedicales.fr › Phénomènes du système immunitaire › Activation des lymphocytes › A phase I/IIa study of the mRNA-based cancer...
questionsmedicales.fr › Personnes › Tranches d'âge › Adulte › Adulte d'âge moyen › A phase I/IIa study of the mRNA-based cancer...
questionsmedicales.fr › Diagnostic › Pronostic › Stadification tumorale › A phase I/IIa study of the mRNA-based cancer...
questionsmedicales.fr › Acides nucléiques, nucléotides et nucléosides › Acides nucléiques › ARN › ARN messager › A phase I/IIa study of the mRNA-based cancer...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Statistiques comme sujet › Analyse de survie › A phase I/IIa study of the mRNA-based cancer...
questionsmedicales.fr › Systèmes sanguin et immunitaire › Système immunitaire › Leucocytes › Agranulocytes › Lymphocytes › Lymphocytes T › A phase I/IIa study of the mRNA-based cancer...